Scientists at the US Food and Drug Administration have outlined a positive stance towards an RSV vaccine developed by Pfizer (NYSE: PFE), ahead of a formal meeting to discuss the firm’s regulatory submission for the candidate.
An earlier panel discussion offered a positive verdict on the product’s use in older adults. The present committee meeting will focus on its use to protect infants.
Should the New York-based pharma major win the agency’s ultimate approval, RSVpreF would become only the second such vaccine to be approved for this kind of viral infection, after GSK’s (LSE: GSK) Arexvy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze